Artiria Medical and the Wyss Center to advance stroke treatment technology

Please login or
register
26.07.2021
stroke
Early-stage medtech startup, Artiria medical, focused on improving stroke treatments has joined forces with the Wyss Center to accelerate the translation of a novel technology that has the potential to reduce deaths and improve quality of life for stroke patients. A new grant from Innosuisse will support the team's development.

Stroke is the third leading cause of disability worldwide, with more than 80 million people living with long-term impairments as a result. Some strokes result in bleeding in the brain. Such hemorrhagic strokes can lead to severe cerebral vasospasm – an uncontrolled contraction of brain arteries - in the days that follow, depriving entire brain regions of blood with devastating consequences. Current treatments for cerebral vasospasm include drugs or angioplasty to stretch the arteries with a balloon, but both have complications, including the risk of additional bleeding.

The new technology developed by Artiria Medical aims to prevent arterial constriction following hemorrhagic stroke. Through a minimally invasive electroactive endovascular probe, the device interacts with specific nerves from within the lower brain arteries to release arterial constriction across the entire brain.

Guillaume Petit-Pierre, CEO at Artiria Medical, said: “There is currently no truly effective solution that can treat cerebral vasospasm following hemorrhagic stroke, yet we know this is a leading cause of disability and death. We believe our technology has the potential to bring a new standard of care to patients and dramatically improve the quality of life after stroke. Now, with the Wyss Center as our partner, we aim to have the technology ready for human trials as fast as possible.”

Artiria Medical has joined forces with the Wyss Center, a non-profit organisation that partners with entrepreneurs to help accelerate their journey from bench to market by contributing resources, expertise and opportunities that influence the entrepreneurial process. The Wyss Center - Artiria Medical collaboration is building on an existing endovascular platform established by the startup. This next-generation technology is centred on a biocompatible expandable system to help safely deliver electrical energy into the targeted arteries. Flexible thin-film electrodes are one of the core enabling technologies of the system. The combined teams’ expertise in electrode development will contribute to the device's ability to precisely control the treatment.

In line with the partnership, the team has received support from Innosuisse, the Swiss Innovation Agency, Innosuisse to test and validate the efficacy of the therapy preclinically in preparation for human clinical studies.

0Comments

More news about

Artiria Medical SA

Company profiles on startup.ch

Artiria Medical SA

rss